BioMarin Pharmaceutical Inc.

Historical 13F Holders

Symbol
BMRN
CUSIP
09061G101
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 09061G101 since 12/18/2024, newest first.

Filer % of Class Filed
Vanguard Capital Management LLC 13G 5.3% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 12 0% 3/26/2026
Event 3/13/2026
BlackRock, Inc. 13G/A Amendment 13 9.1% 1/21/2026
Event 12/31/2025
Viking Global Investors LP 13G/A Amendment 2
4.3% 11/14/2025
Event 9/30/2025
Primecap Management Co/CA/ 13G/A Amendment 25 8.2% 8/14/2025
Event 6/30/2025
Viking Global Investors LP 13G/A Amendment 1
6.4% 8/14/2025
Event 6/30/2025
Capital Research Global Investors 13G/A Amendment 2 4.8% 5/13/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 12 10.8% 4/29/2025
Event 3/31/2025
Capital Research Global Investors 13G/A Amendment 1 6.8% 2/13/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 18 83.8 k $4.99 M
2026 Q2 592 207 M $12.3 B
2026 Q1 587 184 M $10.4 B
2025 Q4 580 189 M $11.2 B
2025 Q3 618 180 M $9.76 B
2025 Q2 630 186 M $10.2 B
2025 Q1 628 187 M $13.1 B
2024 Q4 596 184 M $12.1 B
2024 Q3 614 184 M $12.9 B
2024 Q2 615 189 M $15.6 B
2024 Q1 629 191 M $16.7 B
2023 Q4 608 191 M $18.4 B
2023 Q3 565 183 M $16.5 B
2023 Q2 613 179 M $15.5 B
2023 Q1 608 179 M $17.4 B
2022 Q4 624 188 M $19.5 B
2022 Q3 598 187 M $15.9 B
2022 Q2 582 180 M $14.9 B
2022 Q1 605 179 M $13.8 B
2021 Q4 613 179 M $15.8 B
2021 Q3 551 176 M $13.6 B
2021 Q2 582 177 M $14.8 B
2021 Q1 585 179 M $13.5 B
2020 Q4 613 184 M $16.2 B
2020 Q3 561 180 M $13.7 B
2020 Q2 594 182 M $22.4 B
2020 Q1 564 178 M $15.0 B
2019 Q4 525 176 M $14.9 B
2019 Q3 493 175 M $11.8 B
2019 Q2 544 180 M $15.4 B
2019 Q1 537 179 M $15.9 B
2018 Q4 522 181 M $15.4 B
2018 Q3 511 186 M $18.0 B
2018 Q2 500 184 M $17.4 B
2018 Q1 469 182 M $14.7 B
2017 Q4 478 178 M $15.8 B
2017 Q3 446 175 M $16.3 B
2017 Q2 456 171 M $15.6 B
2017 Q1 456 170 M $14.9 B
2016 Q4 459 170 M $14.1 B
2016 Q3 470 168 M $15.6 B
2016 Q2 436 160 M $12.5 B
2016 Q1 431 166 M $13.4 B
2015 Q4 433 169 M $17.2 B
2015 Q3 435 160 M $16.9 B
2015 Q2 428 158 M $21.6 B
2015 Q1 418 157 M $19.5 B
2014 Q4 374 149 M $13.5 B
2014 Q3 346 148 M $10.7 B
2014 Q2 358 147 M $9.12 B
2014 Q1 344 152 M $10.4 B